Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

The demand for obesity drugs in India is surging as Eli Lilly and Novo Nordisk compete. A Pakistani startup sends prosthetics ...

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone ...

Eli Lilly (NYSE: LLY), which operates a duopoly in the weight loss drug market with Novo Nordisk (NVO), had introduced Mounjaro 2.5 mg and 5 mg vials at 3,500 rupees and 4,375 rupees, respectively.

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to findings published in the New England journal and medicine. Dr ...